



2014 Q1 RESULTS

NET SALES AND BUSINESS EPS




NET SALES BY GROWTH PLATFORM

For Q1 2014



SALES BY GEOGRAPHY

For Q1 2014



MULTIPLE REGULATORY AND PHASE III DEVELOPMENT MILESTONES ARE EXPECTED IN 2014

EXPECTED REGULATORY DECISIONS	Q1	Q2	Q3	Q4
Cerdelga™ in Gaucher disease (U.S. & EU)			■	■
EXPECTED REGULATORY SUBMISSIONS	Q1	Q2	Q3	Q4
Fluzone® QIV Intradermal (U.S.)	■			
Investigational new Insulin U300 in Diabetes (U.S. & EU)		■		
6-in-1 vaccine PR5I (U.S.)			■	
EXPECTED HEADLINE PHASE III DATA RELEASES	Q1	Q2	Q3	Q4
Alirocumab in Hypercholesterolemia (multiple ODYSSEY trials)		■	■	
Dengue vaccine trials in Latin America and Asia			■	■
EXPECTED PHASE III STARTS	Q1	Q2	Q3	Q4
LixiLan (lixisenatide + insulin glargine) in Diabetes	■			
Dupilumab in Atopic Dermatitis			■	■
Rotavirus vaccine				■

For full financial data and non-GAAP reconciliations, please refer to Sanofi's Q1 Update Results and Presentation issued April 29, 2014, available at <http://en.sanofi.com/investors/investors.aspx>



For more information, visit www.sanofi.us